The number of genomic alterations recommended for therapy guidance in BC has steadily increased, with PIK3CA mutations, ERBB2 amplifications, NTRK fusions, MSI, TMB and ESR1 variants currently available (Table 15). Here, ESR1 is linked to breast cancer.